Millennium Management LLC lowered its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 88.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 12,527 shares of the company's stock after selling 98,416 shares during the quarter. Millennium Management LLC's holdings in Entrada Therapeutics were worth $217,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of the business. Janus Henderson Group PLC lifted its stake in shares of Entrada Therapeutics by 21.6% in the 4th quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company's stock valued at $36,011,000 after purchasing an additional 368,908 shares during the period. Vanguard Group Inc. lifted its stake in shares of Entrada Therapeutics by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock valued at $25,317,000 after purchasing an additional 241,052 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in shares of Entrada Therapeutics by 123.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 222,520 shares of the company's stock valued at $3,847,000 after purchasing an additional 122,823 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Entrada Therapeutics by 127.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 217,006 shares of the company's stock valued at $3,752,000 after purchasing an additional 121,598 shares during the period. Finally, Federated Hermes Inc. lifted its stake in shares of Entrada Therapeutics by 3,104.3% in the 4th quarter. Federated Hermes Inc. now owns 99,814 shares of the company's stock valued at $1,726,000 after purchasing an additional 96,699 shares during the period. Hedge funds and other institutional investors own 86.39% of the company's stock.
Entrada Therapeutics Price Performance
TRDA stock traded down $0.26 on Friday, reaching $7.59. 117,868 shares of the company traded hands, compared to its average volume of 133,258. Entrada Therapeutics, Inc. has a one year low of $7.10 and a one year high of $21.79. The company has a market cap of $288.06 million, a P/E ratio of 4.77 and a beta of -0.06. The firm has a fifty day simple moving average of $8.21 and a 200-day simple moving average of $11.93.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The company had revenue of $8.75 million during the quarter, compared to analyst estimates of $10.98 million. On average, sell-side analysts forecast that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.
Analyst Upgrades and Downgrades
TRDA has been the subject of a number of research analyst reports. Wall Street Zen cut Entrada Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday, May 20th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $25.67.
Get Our Latest Report on Entrada Therapeutics
Entrada Therapeutics Profile
(
Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Articles

Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.